App-Quantinova.ai

Protective Effects of the Natural Antioxidant Taxifolin in Models of Lupus and Antiphospholipid Syndrome

Christine Rysenga - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Milk thistle

Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients

Reid Weisberg - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis

Hugh Alessi - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Cecile Yelnik - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study

Lea Hoisnard - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Adalimumab

Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database

Eiichi Tanaka - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

ABT-494

The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis

Jean Liew - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA

Patrick Durez - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Filgotinib

Elevated C-Reactive Protein Level Amplifies the Association of Lipoprotein(a) With Cardiovascular Risk and Risk Reduction With Alirocumab After Acute Coronary Syndrome

Gregory G Schwartz - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Alirocumab

Inhibition of Plasminogen Activator Inhibitor Type 1 in Experimental Venous Thrombosis

Maxim E Shaydakov - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Enoxaparin

Identifying Sources of Prostacyclin Outside the Vascular Wall and Their Contribution to Cardiovascular Protection

Maria Lopes Pires - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Prostacyclin

Pulmonary Vein Thrombosis A Rare Complication Following Infection With SARS-CoV-2

Mithun R Suresh - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Heparin

The Lingering Snag in Era of Mechanical Pumps A Case of Acute Pump Thrombosis Immediately After Heartmate 3 Implantation

Anureet Malhotra - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Dobutamine

Acquired Hemophilia A and STEMI A Management Dilemma

Jevin Yabut - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

rFVIIa

Spontaneous Heparin-Induced Thrombocytopenia Presenting as Acute Stent Thromboses Following an Acute St-Segment Elevation Myocardial Infarction

Chad Gier - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Cardiac Complications in Polyarteritis Nodosa A Case of Multi-Vessel Coronary Occlusion Treated With 4-Vessel Coronary Artery Bypass Grafting

Dylan J Walter - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Cyclophosphamide

Dissecting Out Risk Factors A Case of Spontaneous Coronary Artery Dissection Without Traditional Risk Factors, in the Presence of Methamphetamine Use

Mohammed Ali - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Methamphetamine

Quantitative Whole Blood Platelet Aggregation Predicts Occurrence of Subacute Thrombosis in Patients After Percutaneous Coronary Intervention

Nobusada Funabashi - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Adenosine

Efficacy and Safety of Cangrelor in Patients Undergoing PCI After Cardio-Pulmonary Resuscitation and/or Cardiogenic Shock. Results of the CAN-SHOCK Registry

Uwe Zeymer - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

cangrelor

Impact of Epinephrine Administration Route on the Outcomes of Cardiac Resuscitation of Acute Myocardial Infarction Patients With Cardiac Arrest in the Cardiac Catheterization Laboratory (iCPR Study)

Ayman Haq - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Epinephrine

Filters

7277 Abstracts